Detalles de la búsqueda
1.
Differential effects of anti-CD20 therapy on CD4 and CD8 T cells and implication of CD20-expressing CD8 T cells in MS disease activity.
Proc Natl Acad Sci U S A;
120(3): e2207291120, 2023 01 17.
Artículo
en Inglés
| MEDLINE | ID: mdl-36634138
2.
Prior treatment status: impact on the efficacy and safety of teriflunomide in multiple sclerosis.
BMC Neurol;
20(1): 364, 2020 Oct 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-33023488
3.
Evaluation of sumatriptan-naproxen in the treatment of acute migraine: a placebo-controlled, double-blind, cross-over study assessing cognitive function.
Headache;
53(4): 656-64, 2013 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-23406052
4.
Multiple environmental factors, but not nutrient addition, directly affect wet grassland soil microbial community structure: a mesocosm study.
FEMS Microbiol Ecol;
99(7)2023 06 16.
Artículo
en Inglés
| MEDLINE | ID: mdl-37355783
5.
COVID-19 mRNA vaccination leading to CNS inflammation: a case series.
J Neurol;
269(3): 1093-1106, 2022 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-34480607
6.
Discontinuation of disease modifying therapies is associated with disability progression regardless of prior stable disease and age.
Mult Scler Relat Disord;
57: 103406, 2022 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-34915316
7.
A phase 3 trial of extended release oral dalfampridine in multiple sclerosis.
Ann Neurol;
68(4): 494-502, 2010 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-20976768
8.
Exacerbation of Multiple Sclerosis by BRAF/MEK Treatment for Malignant Melanoma: The Central Vein Sign to Distinguish Demyelinating Lesions From Metastases.
J Investig Med High Impact Case Rep;
9: 23247096211033047, 2021.
Artículo
en Inglés
| MEDLINE | ID: mdl-34308699
9.
A pharmacokinetic and biomarker study of delayed-release dimethyl fumarate in subjects with secondary progressive multiple sclerosis: evaluation of cerebrospinal fluid penetration and the effects on exploratory biomarkers.
Mult Scler Relat Disord;
51: 102861, 2021 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-33773271
10.
Manifestations and impact of the COVID-19 pandemic in neuroinflammatory diseases.
Ann Clin Transl Neurol;
8(4): 918-928, 2021 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-33616290
11.
Neurofilament light chain as an indicator of exacerbation prior to clinical symptoms in multiple sclerosis.
Mult Scler Relat Disord;
31: 59-61, 2019 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-30927733
12.
Morphology and genetics of Lythrum salicaria from latitudinal gradients of the Northern Hemisphere grown in cold and hot common gardens.
PLoS One;
14(1): e0208300, 2019.
Artículo
en Inglés
| MEDLINE | ID: mdl-30605466
13.
Efficacy and Safety of Alemtuzumab in Patients of African Descent with Relapsing-Remitting Multiple Sclerosis: 8-Year Follow-up of CARE-MS I and II (TOPAZ Study).
Neurol Ther;
8(2): 367-381, 2019 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-31654272
14.
Teriflunomide real-world evidence: Global differences in the phase 4 Teri-PRO study.
Mult Scler Relat Disord;
31: 157-164, 2019 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-31005729
15.
Safety and efficacy of opicinumab in patients with relapsing multiple sclerosis (SYNERGY): a randomised, placebo-controlled, phase 2 trial.
Lancet Neurol;
18(9): 845-856, 2019 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-31285147
16.
Real-World Observational Evaluation of Hair Thinning in Patients with Multiple Sclerosis Receiving Teriflunomide: Is It an Issue in Clinical Practice?
Neurol Ther;
7(2): 341-347, 2018 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-30084001
17.
Patient-reported outcomes in patients with relapsing forms of MS switching to teriflunomide from other disease-modifying therapies: Results from the global Phase 4 Teri-PRO study in routine clinical practice.
Mult Scler Relat Disord;
26: 211-218, 2018 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-30273841
18.
Maximally tolerated versus minimally effective dose: the case of rituximab in multiple sclerosis.
Mult Scler;
18(3): 377-8, 2012 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-21828201
19.
Patient-reported outcomes in relapsing forms of MS: Real-world, global treatment experience with teriflunomide from the Teri-PRO study.
Mult Scler Relat Disord;
17: 107-115, 2017 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-29055438
20.
Rationale for combination therapy with galantamine and memantine in Alzheimer's disease.
J Clin Pharmacol;
46(7 Suppl 1): 17S-26S, 2006 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-16809811